CXCL8 and Guillain-Barre syndrome: We found a correlation between pre-treatment levels of IL8, and disease severity measured with GBS-ds at the time of sampling (Spearman coefficient r = 0.78, p = 0.0002), and nadir (r = 0.86, p < 0.0001), as well as outcome at 3-months follow-up (r = 0.62, p = 0.009), 6-months (r = 0.53, p = 0.03), and EGOS prognostic score (r = 0.66, p = 0.003) (Figure 4).